More Company News

Oxford BioDynamics

UK MHRA CTA for iSCIB1+ Phase III in advanced melanoma
19 Aug 2026Read More

Oxford BioDynamics

Positive top line SAFFRON Phase III data
17 Aug 2026Read More

Oxford BioDynamics

Partnership with Dubai London Clinics & Hospitals
13 Aug 2026Read More

Oxford BioDynamics

Fundraising, posting of circular & notice of GM
10 Aug 2026Read More

Oxford BioDynamics

Eroxon Intense EU market launch clearance
31 Jul 2026Read More

Oxford BioDynamics

H126 interim results
30 Jul 2026Read More

Oxford BioDynamics

First commercial agreement for EpiSwitch Orion
28 Jul 2026Read More

Oxford BioDynamics

Result of Retail Offer and Total Voting Rights
27 Jul 2026Read More

Oxford BioDynamics

Oversubscribed UK placing raises £13m
23 Jul 2026Read More

Oxford BioDynamics

Neuphoria merger and financing
23 Jul 2026Read More

1 2 3 4 … 98
Return to Oxford BioDynamics
© 2019-2026 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).